The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Abbott Laboratories' revenues will increase 2.3% and EPS will improve 8.9%.
The average estimate for revenue is $9.83 billion. On the bottom line, the average EPS estimate is $1.22.
Last quarter, Abbott Laboratories notched revenue of $9.46 billion. GAAP reported sales were 4.6% higher than the prior-year quarter's $9.04 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.03. GAAP EPS of $0.78 for Q1 were 42% higher than the prior-year quarter's $0.55 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 60.6%, 270 basis points better than the prior-year quarter. Operating margin was 18.2%, 140 basis points better than the prior-year quarter. Net margin was 13.1%, 350 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $39.83 billion. The average EPS estimate is $5.04.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,558 members out of 2,652 rating the stock outperform, and 94 members rating it underperform. Among 697 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 681 give Abbott Laboratories a green thumbs-up, and 16 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Abbott Laboratories is outperform, with an average price target of $61.86.
- Add Abbott Laboratories to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Abbott Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Fastest-Growing Diabetes Stocks of 2018 -- According to Wall Street
Analysts think these three diabetes stocks could soar more than 50% this year. But are they right?
This News Explains Why DexCom Is Dropping Today
Shares slide after news breaks that a competitor's product nabs an important reimbursement win.
3 Top Diabetes Stocks to Buy Now
The diabetes market is growing. And these stocks are poised to grow with it.